I-Tirzepatideiyinoveli eyi-agonist ekabili ye-GIP kanye ne-GLP-1 receptors, egunyazwe ukulawulwa kwe-glycemic kubantu abadala abanesifo sikashukela sohlobo 2 kanye nokulawulwa kwesisindo sesikhathi eside kubantu abane-body mass index (BMI) ≥30 kg/m², noma ≥27 kg/m² okungenani okukodwa okuhambisana nesisindo.
Ngesifo sikashukela, yehlisa kokubili i-glucose yokuzila kanye ne-postprandial ngokubambezela ukuphuma kwesisu, ithuthukise ukukhiqizwa kwe-insulin ethembele ku-glucose, futhi icindezele ukukhululwa kwe-glucagon, ngengozi ephansi ye-hypoglycemia uma kuqhathaniswa ne-secretagogue ye-insulin yendabuko. Ekulawulweni kokukhuluphala ngokweqile, izenzo zayo ezimbili ezimaphakathi neziseduze zinciphisa isifiso sokudla futhi andise ukusetshenziswa kwamandla. Izivivinyo zemitholampilo zibonise ukuthi amasonto angama-52-72 okwelashwa angafinyelela isilinganiso sokunciphisa isisindo somzimba ngo-15% -20%, okuhambisana nokuthuthukiswa komjikelezo wokhalo, umfutho wegazi, kanye ne-triglycerides.
Izehlakalo ezingezinhle ezivame kakhulu izimpawu zesisu ezithambile kuya kwezimaphakathi, ezivame ukwenzeka emasontweni ambalwa okuqala futhi zehliswa ukwenyuka komthamo kancane kancane. Ukuqaliswa komtholampilo kunconywa ngaphansi kokuhlolwa kwe-endocrinologist noma uchwepheshe wokulawula isisindo, ngokuqapha okuqhubekayo kwe-glucose, isisindo somzimba, nokusebenza kwezinso. Sekukonke, i-tirzepatide inikeza inketho yokwelapha esekelwe ebufakazini, ephephile, futhi eqhubekayo ezigulini ezidinga kokubili ukulawulwa kwe-glycemic nesisindo.
Isikhathi sokuthumela: Aug-27-2025